Junli Zhang(张均利)

Junli Zhang(张均利) (senior executive) discloses dealings in 泽璟制药 to SSE / SZSE (CSRC). In total, 7 filings cover trades dated from 11 March 2022 to 7 July 2022.

On the market, this insider has only ever bought: 7 purchases, €128k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price.

In size, the median ticket on the buying side is €14k. 6 out of 7 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 7 July 2022, the filings show an open-market purchase worth €1,072 in 泽璟制药. Publication is fast: at least half of the trades appear on SSE / SZSE (CSRC) on the same day. This delay matters because a trade only becomes useful information once it is public. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.